Seroprevalence of SARS CoV-2 infections/Covid-19 in blood donors and patients of the University Hospitals in Leipzig
- Conditions
- U07.1COVID-19, virus identified
- Registration Number
- DRKS00023364
- Lead Sponsor
- Institut für Medizinische Mikrobiologie und Virologie, Universitätsklinikum Leipzig
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting withdrawn before recruiting started
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Four groups of individuals:
1. All patients at the University Hospital from which blood has been taken for medical reasons
2. Blood donors
3. Patients from the neurologic walk-in clinic
4. Patients with advanced liver disease
Exclusion Criteria
Serum and plasma samples that are not suitable for technical reasons
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IgG antibody response to SARS CoV-2 will be tested using an antibody test (e. g. ELISA)
- Secondary Outcome Measures
Name Time Method o other measurements
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie SARS-CoV-2 seroprevalence trends in DRKS00023364 blood donor cohorts?
How do anti-SARS-CoV-2 antibody profiles in DRKS00023364 compare to standard-of-care vaccine-induced immunity markers?
What biomarkers correlate with seroprevalence outcomes in DRKS00023364 hospitalized vs asymptomatic patient subgroups?
What adverse event management strategies are associated with SARS-CoV-2 seroprevalence monitoring in observational studies?
How do combination approaches involving SARS-CoV-2 serological testing and PCR diagnostics impact early detection rates in DRKS00023364?